Genentech, a biologics drugmaker owned by Roche, will slash 130 jobs or about 13 percent of its workforce at its Vacaville, Calif. plant as the company faces increased biosimilar competition, according to STAT.
"We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments," a Genentech spokeswoman told STAT.
The company will reduce its workforce by the end of the year.